Clinical trials drive drug development, but traditional assessments focus on major milestones—walking, talking—while overlooking smaller yet meaningful "inchstones." For individuals with profound conditions like Developmental and Epileptic Encephalopathies (DEE), more sensitive and specific measurements are crucial. As parents, we see these subtle changes firsthand. In order for treatments that work to address what matters most to families, we need better tools to accurately capture these incremental but significant improvements. It is our mission to build them.